Cardiology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBER - CV), Spain.
Cardiol J. 2022;29(2):293-304. doi: 10.5603/CJ.a2021.0172. Epub 2021 Dec 30.
Long-term continuous-flow left ventricular assist devices have become a real alternative to heart transplantation in patients with advanced heart failure, achieving a promising 2-year event-free survival rate with new-generation devices. Currently, this technology has spread throughout the world, and any cardiologist or cardiac surgeon should be familiar with its fundamentals and its possible complications as well as the advances made in recent years. The aim of this review is to describe current knowledge, management of complications, and future directions of this novel heart-failure therapy.
长期持续的左心室辅助装置已成为晚期心力衰竭患者心脏移植的一种真正选择,新一代装置实现了有前景的 2 年无事件生存率。目前,这项技术已经在全球范围内得到推广,任何心脏病专家或心脏外科医生都应该熟悉其基本原理及其可能出现的并发症,以及近年来取得的进展。本文的目的是描述这种新型心力衰竭治疗的现有知识、并发症的处理和未来方向。